
RealRate

PHARMACEUTICAL 2018

Histogen Inc. Rank 97 of 349







PHARMACEUTICAL 2018

Histogen Inc. Rank 97 of 349



The relative strengths and weaknesses of Histogen Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Histogen Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 219% points. The greatest weakness of Histogen Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 119% points.

The company's Economic Capital Ratio, given in the ranking table, is -21%, being 256% points above the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	79,224
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	28,142
Liabilities, Non-Current	0
Other Assets	2,538
Other Compr. Net Income	-71
Other Expenses	0
Other Liabilities	0
Other Net Income	154
Property and Equipment	179
Research and Development	43,220
Revenues	35,377
Selling, General and Administrative Expense	9,707

Output Variable	Value in 1000 USD
Assets	81,941
Liabilities	28,142
Expenses	52,927
Stockholders Equity	53,799
Net Income	-17,396
Comprehensive Net Income	-17,432
Economic Capital Ratio	-21%